Paper: Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML
This is a retrospective analysis of patients with secondary AML with prior HMA exposure treated with either AZA/VEN, low intensity treatment or higher intensity treatment. Pateints treated with high intensity treatment were a median 7 years younger. Cr/CRi rate was 26% adn ORR was 34% in the entire cohort, with similar rates between intensive and low intensity chemotherapy. HMA+Ven was associated with higher CR/CRi rates (39% vs 25%) and ORR (54% vs 33%). Similarly, OS was superior for the patients treated with HMA+Ven (median OS 5.8 months).
